EUVIMEDEUVIMED entdecken
Crossref

Site-specific nanoswitch circumventing immune resistance via activating TLR and inhibiting PD-L1/PD-1 axis

Yanyun Hao, Hui Li, Xiaoyan Ge, Yang Liu, Jialin Yin, Xia Li, Yutong Liu, Hongfei Chen, Lingling Huang, Jing Zou, Shiying Zhang, Hao Wu und 1 weitere

Journal of Controlled Release · 2023

DOI: 10.1016/j.jconrel.2023.07.048 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2023. Verfasst von Yanyun Hao und 12 weiteren Autor:innen. Beteiligte Einrichtung: NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology (Ministry of Education), Department o…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has fundamentally altered cancer treatment; however, its effectiveness is clinically hampered by insufficient intratumoral T lymphocyte infiltration and failed T lymphocyte priming. Additionally, inducing cancer-specific immune responses while sparing normal cells remains challenging. Herein, we developed a redox-activatable polymeric nanoswitch (c-N@IM/JQ) that remained 'off' status in circulation but rapidly switched 'on' after entering the tumor. Toll-like receptor (TLR) 7/8 agonist (imidazoquinoline, IMQ) and bromodomain and extraterminal inhibitor (JQ1) are locked in c-N@IM/JQ with a redox-cleavable linker (switch off). Upon systemic administration, c-N@IM/JQ with c-RGD peptide modification preferentially accumulated at tumor sites and responded to the high glutathione levels to release native IMQ for fully mobilizing T lymphocyte army, and JQ1 for removing the programmed death ligand (PD-L)-1 protection on tumor cells (switch on). These strengthened T lymphocyte armies are easily accessible to these de-protected tumor cells, revitalizing the immune response against tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorNeoplasmsHumansB7-H1 AntigenT-LymphocytesImmunotherapyAdjuvants, ImmunologicTumor Microenvironment

Stichwörter der Autor:innen

Polymeric nanoswitchRedox-cleavable linkerT lymphocyte armiesT lymphocyte dysfunction

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenAdjuvants, Immunologic

Autor:innen und Institutionen

  • NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of…
  • Department of Nutrition and Food Hygiene, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, PR China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Hao, Y., Li, H., Ge, X., Liu, Y., Yin, J., Li, X., Liu, Y., Chen, H., Huang, L., Zou, J., Zhang, S., Wu, H., & Zhang, Z. (2023). Site-specific nanoswitch circumventing immune resistance via activating TLR and inhibiting PD-L1/PD-1 axis. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2023.07.048

Vancouver

Hao Y, Li H, Ge X, Liu Y, Yin J, Li X, et al. Site-specific nanoswitch circumventing immune resistance via activating TLR and inhibiting PD-L1/PD-1 axis. Journal of Controlled Release. 2023. doi:10.1016/j.jconrel.2023.07.048

BibTeX
@article{Hao2023,
  author = {Hao, Yanyun and Li, Hui and Ge, Xiaoyan and Liu, Yang and Yin, Jialin and Li, Xia and Liu, Yutong and Chen, Hongfei and Huang, Lingling and Zou, Jing and Zhang, Shiying and Wu, Hao and Zhang, Zhiyue},
  title = {Site-specific nanoswitch circumventing immune resistance via activating TLR and inhibiting PD-L1/PD-1 axis},
  journal = {Journal of Controlled Release},
  year = {2023},
  doi = {10.1016/j.jconrel.2023.07.048}
}
Kostenlos starten →